In-depth interviews and commentary on the global biopharma business

Scrip podcast specials

Scrip writers Joseph Haas and Jessica Merrill discuss US FTC overview of biopharma mergers like Amgen/Horizon and Pfizer/Seagen with Leerink Partners' analyst Dan Lepanto and ZS Associates partner Cody Powers.

Scrip M&A Podcast: US FTC Review of Mergers and Acquisitions

Syngene’s MD & CEO, Jonathan Hunt, in an interview with Scrip, dissects trends and opportunities in the CRDMO segment as US biotechs slow their burn rate amid a funding squeeze while other large and medium-sized biopharma firms seek to rebalance their supply chain. The Indian firm’s ability to add value in the development and manufacture of ADCs and also its partnership with Amgen are some of the other topics the ex-AstraZeneca executive discusses.

Syngene CEO On Sub-Dynamics As US Biotech Funding Finds New Normal, ADC Capabilities

In accepting Scrip’s Lifetime Achievement Award, Ovid Therapeutics’ CEO called on pharma to show responsible leadership and live up to its potential to do good for society.

Scrip Lifetime Achievement Award 2023: Jeremy Levin’s Acceptance Speech

In this podcast Scrip looks at the some upcoming clinical catalysts for biopharma, judged by the size of the sales forecasts at stake. Companies including Sanofi, Cytokinetics, Corcept and Inventiva stand to gain – or lose.

Biopharma’s Must-Know 2023-4 Catalysts

Scrip’s senior editor Vibha Ravi speaks with Jack Hoppin, CEO and chairman, and John Babich, chief scientific officer, at Ratio Therapeutics, about the company’s radiopharmaceuticals pipeline, investment by BMS, use of AI, trends and developments in radiopharma research like combining ADCs or PARP inhibitors and more.
https://scrip.citeline.com/SC150098/Ratio-Therapeutics-On-BMS-Investment-Radiopharma-RD-Trends-AI-Use

Ratio Therapeutics On BMS Buy-In, Radiopharma R&D Trends, AI And Assets

Scrip's Joseph Haas, Kevin Grogan and Edwin Elmhirst talk about the biopharma M&A environment and which companies might look particularly appealing to potential acquirers.

Scrip M&A Podcast: Are Buyers Coming For Viking, Verona, Altimmune, Xenon And Crinetics

Citeline places biopharma and medical device professionals, and those who focus on these industries, at the forefront of knowledge and insight, by providing the perfect combination of news and information together with penetrating insight and analysis. Citeline is a leader in the field of healthcare industry information.